Title
Category
Credits
Event date
Cost
Venous Thromboembolism Management in Malignancy
  • Venous Thromboembolic Disease
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Clinical staff should be knowledgeable in factors that enhance VTE risk and be able to counsel patients regarding risk factors that are modifiable. They should also understand appropriate prophylaxis regimens for high-risk patients and be educated on the signs associated with the diverse subtypes of VTE and their best courses of treatment.
Updates in Melanoma: A Focus on Neoadjuvant Approaches
  • Melanoma
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
With new regimens emerging as viable options for neoadjuvant therapy, clinicians should be aware of the changing landscape in initial cutaneous melanoma treatment options. It will be essential for the clinician to identify patients who would benefit from neoadjuvant intervention versus a more traditional surgical or systemic therapy approach.
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies
  • Management of Immunotherapy-Related Toxicities
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As these therapies continue to evolve, it is imperative that nursing policies are created/revised and shared with nursing staff to remain up to date on current clinical practice for these complications. With continued education and reinforcement of protocols, nurses can positively impact patient outcomes.
Advances in Antiemesis Management for Patients with Cancer
  • Supportive Care Topics
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Recent clinical trials continue to enhance available data on the use of olanzapine for emesis prevention in parenteral anticancer agents with high and moderate emetogenic risk as well as for breakthrough treatment and an alternative to dexamethasone for delayed anticancer induced nausea/vomiting. Clinicians should be aware of these updates and how they apply to appropriate patients.
Management of Immune Checkpoint Inhibitor-Related Toxicities
  • Management of Immunotherapy-Related Toxicities
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The landscape of cancer care has undergone a dramatic shift, due to the availability and increased use of immunotherapy agents such as immune checkpoint inhibitors (ICIs). As more patients become eligible to receive ICIs, clinicians need to be able to recognize immune-mediated adverse events (irAEs) and remain informed about the most up-to-date strategies for managing these toxicities.
Updates in Metastatic Colorectal Cancer
  • Colorectal Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As options for treatment of metastatic colorectal cancer evolve, clinicians can benefit from education about available options and criteria for selecting the appropriate option to offer their patients. An overview of these newer treatment options, and the data supporting these, should help clinicians better serve their patients with metastatic colorectal cancer.
Recorded Presentations from the NCCN 2025 Annual Conference
$0.00
The NCCN 2025 Annual Conference addressed timely and important educational needs of cancer care providers to improve and facilitate quality, effective, equitable and accessible cancer care so patients can live better lives.The conference focuses on the practical management of patients living with or at risk for cancer, provides updates of NCCN Guidelines, and includes educational sessions on new treatments, therapies, and trends, and their application in patient care. The conference also provides a venue for education around best practices for cancer care delivery.
Treatment Updates for Small Cell Lung Cancer
  • Lung Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
After decades of no change in treatment, practice changing therapies have now been added to the NCCN Guidelines for Small Cell Lung Cancer. This activity will help clinicians keep up to date with practice-changing strategies for SCLC.
Plenary Session: Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance
  • Best Practices
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
$0.00
Education in this topic is important as AI is increasingly incorporated into care settings. Practitioners may not be aware of the way AI is currently being used or of its potential future application. Additionally, healthcare professionals need to be informed of the policy environment for the safe and effective use of AI in healthcare settings.
Artificial Intelligence: Evaluation and Success Criteria for AI Tools
  • Best Practices
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
With the promise of artificial intelligence (AI) and its potential to positively impact healthcare, comes the challenge of how to assess the feasibility and value associated with implementation of AI tools.

Pages